Epidermal Growth Factor Receptor Mutations detection by Mutant Specific Immunohistochemistry in North Indian Lung Cancer population
DOI:
https://doi.org/10.21276/IJRDPL.2278-0238.2017.6(6).2796-2799Keywords:
Lung Cancer, EGFR, Non-small Cell Lung Cancer, Subtype, DiagnosisAbstract
Background: Lung cancer is one of the leading causes of cancer-related deaths due to limited treatment options available for advanced-stage disease. The epidermal growth factor receptor is a trans-membrane glycoprotein having an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain which regulates signaling pathways to control cellular proliferation.
Material and Methods: Detection of EGFR mutation status of 80 subjects of non-small cell lung cancer of adenocarcinoma subtype had been done by IHC using EGFR mutation specific antibodies.
Results: 20 cases were positive for Del E746-A750 mutation, 6 for L858R mutation. IHC analysis shows that 30 cases scored 0, 12 cases scored 2+ and 8 cases scored 3+ in Del E746-A750 mutation while 24 cases scored 0, 1 case scored 2+ and 5 cases scored 3+ in L858R mutation. The mean age of mutation positive is 56±9.50 and negative is 53.37±11.83. 65.38% male and 34.61% female were positive for EGFR mutation. The study shows that 8 (30.77%) ex/ current smokers and 18 (69.2%) nonsmokers were positive for EGFR mutations.
Conclusion: Patients who were positive for EGFR mutation can take gefitinib treatment instead of taking other chemotherapy regimen. This is a rapid method for diagnosis of lung cancer patients and helpful in the treatment decision which improve the burden of the disease.
Downloads
References
Jamal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res ClinOncol 2008; 134:469-77.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129–2139.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497–1500.
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl AcadSci U S A 2004, 101(36):13306–13311.
Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169–181.
Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, Duan J, Yang L, Wu M, Liang Z, Wang Y, Kang X, Wang J: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J ClinOncol 2012, 30(25):3077–3083.
Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J ClinOncol 2009, 27(16):2653–2659.
Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J ClinOncol 2005; 23:2513–20.
Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J ClinOncol 2005; 23:6829–37.
Yong Hannah Wen, Edi Brogi, Adnan Hasanovic, Marc Ladanyi, Robert A Soslow, Dhananjay Chitale, Jinru Shia and Andre L Moreira. Immuno histochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Modern Pathology (2013) 26, 1197–1203.
Guiyang Jiang, Chuifeng Fan, Xiupeng Zhang et al. Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer. PLo One. 2013;8(3): e59183.
How to cite this article:
Gaur P, Bhattacharya S, Surya Kant, Kushwaha RAS, Agarwal J and Pathak AK. Epidermal Growth Factor Receptor Mutations Detection by Mutant Specific Immunohistochemistry in North Indian Lung Cancer population. Int. J. Res. Dev. Pharm. L. Sci. 2017; 6(6): 2796-2799. Doi: 10.13040/IJRDPL.2278-0238.6(6). 2796-2799.
This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
.